skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

Abstract

The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Inventors:
;
Publication Date:
Research Org.:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States); UNM Rainforest Innovations, Albuquerque, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1860015
Patent Number(s):
11,160,887
Application Number:
16/267,477
Assignee:
UNM Rainforest Innovations (Albuquerque, NM)
DOE Contract Number:  
AC52-06NA25396
Resource Type:
Patent
Resource Relation:
Patent File Date: 02/05/2019
Country of Publication:
United States
Language:
English

Citation Formats

Miao, Yubin, and Guo, Haixun. Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same. United States: N. p., 2021. Web.
Miao, Yubin, & Guo, Haixun. Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same. United States.
Miao, Yubin, and Guo, Haixun. 2021. "Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same". United States. https://www.osti.gov/servlets/purl/1860015.
@article{osti_1860015,
title = {Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same},
author = {Miao, Yubin and Guo, Haixun},
abstractNote = {The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.},
doi = {},
url = {https://www.osti.gov/biblio/1860015}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Nov 02 00:00:00 EDT 2021},
month = {Tue Nov 02 00:00:00 EDT 2021}
}

Works referenced in this record:

Cyclic analogs of alpha-MSH fragments
patent, October 1997


Therapeutic Radiopharmaceuticals
journal, September 1999


Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues
journal, October 2003


Yttrium-90-labelled somatostatin-analogue for cancer treatment
journal, February 1998


Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer
journal, March 2007


Impact of PKM Linkers on Biodistribution Characteristics of the 99mTc-Labeled Cyclic RGDfK Dimer
journal, November 2006


Design of a new class of superpotent cyclic .alpha.-melanotropins based on quenched dynamic simulations
journal, April 1989


Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases
journal, February 2000


Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide
journal, January 2007


Design of cyclic and other templates for potent and selective peptide α-MSH analogues
journal, August 2005


Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging
journal, January 2007


Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues
journal, August 2006


In vivo evaluation of188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy
journal, September 2002


Microimaging Characterization of a B16-F10 Melanoma Metastasis Mouse Model
journal, April 2006


[half-Cys4,half-Cys10]-alpha-Melanocyte-stimulating hormone: a cyclic alpha-melanotropin exhibiting superagonist biological activity.
journal, March 1982


Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
journal, August 2001


Method of Inducing Melanogenesis in Humans With Mc1R Variant Alleles
patent-application, January 2008


Specific Receptors for α-Melanocyte-Stimulating Hormone Are Widely Distributed in Tissues of Rodents
journal, November 1987


Melanoma Therapy via Peptide-Targeted  -Radiation
journal, August 2005


Potent and prolonged-acting cyclic lactam analogs of .alpha.-melanotropin: design based on molecular dynamics
journal, December 1989


111In-Labeled Lactam Bridge-Cyclized α-Melanocyte Stimulating Hormone Peptide Analogues for Melanoma Imaging
journal, January 2008


Cancer Statistics, 2007
journal, January 2007


Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model
journal, July 2005


Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide
journal, April 2009


DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
journal, July 1997


Design and characterization of  -melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
journal, October 1998


In Vitro and In Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging
journal, February 2004


Molecular imaging of gene expression and protein function in vivo with PET and SPECT
journal, September 2002


Molecular imaging of cancer with positron emission tomography
journal, September 2002


Metastasis Results from Preexisting Variant Cells Within a Malignant Tumor
journal, August 1977


Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides
journal, August 2006


Imaging of Melanoma Using 64Cu− and 86Y−DOTA−ReCCMSH(Arg11), a Cyclized Peptide Analogue of α-MSH
journal, March 2005